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abstract: Pre-eclampsia is a serious complication of pregnancy that can affect bothmaternal and fetal outcomes. Early-onset pre-eclampsia
(EOPET) is a severe form of pre-eclampsia that is associated with altered physiological characteristics and gene expression in the placenta. DNA
methylation is a relatively stable epigenetic modiﬁcation to DNA that can reﬂect gene expression, and can provide insight into the mechanisms
underlying such expression changes. This case–control study focused onDNAmethylation and gene expression of whole chorionic villi samples
from 20 EOPET placentas and 20 gestational age-matched controls from pre-term births. DNA methylation was also assessed in placentas
affected by late-onset pre-eclampsia (LOPET) and normotensive intrauterine growth restriction (nIUGR). The Illumina HumanMethylation450
BeadChipwasused to assessDNAmethylation at.480 000 cytosine-guanine dinucleotide (CpG) sites. The IlluminaHT-12v4 ExpressionBead-
Chip was used to assess gene expression of.45 000 transcripts in a subset of cases and controls. DNAmethylation analysis by pyrosequencing
was used to follow-up the initial ﬁndings in four genes with a larger cohort of cases and controls, including nIUGR and LOPET placentas. Bioinfor-
matic analysis was used to identify overrepresentation of gene ontology categories and transcription factor binding motifs. We identiﬁed 38 840
CpG siteswith signiﬁcant (false discovery rate,0.01)DNAmethylation alterations in EOPET, of which 282 had.12.5%methylation difference
comparedwith the controls. Signiﬁcant siteswereenrichedat theenhancers and lowCpGdensity regionsof the associated genes and themajority
(74.5%)of these siteswerehypomethylated inEOPET.EOPET,butnot associated clinical features, such as intrauterine growth restriction (IUGR),
presented a distinct DNA methylation proﬁle. CpG sites from four genes relevant to pre-eclampsia (INHBA, BHLHE40, SLC2A1 and ADAM12)
showed different extent of changes in LOPET and nIUGR. Genome-wide expression in a subset of samples showed that some of the gene ex-
pression changes were negatively correlated with DNA methylation changes, particularly for genes that are responsible for angiogenesis (such
as EPAS1 and FLT1). Results could be confounded by altered cell populations in abnormal placentas. Larger sample sizes are needed to fully
address the possibility of sub-proﬁles of methylation within the EOPET cohort. Based on DNA methylation proﬁling, we conclude that there
are widespread DNA methylation alterations in EOPET that may be associated with changes in placental function. This property may provide
a useful tool for early screening of such placentas. This study identiﬁes DNA methylation changes at many loci previously reported to have
altered gene expression in EOPET placentas, as well as in novel biologically relevant genes we conﬁrmed to be differentially expressed. These
results may be useful for DNA- methylation-based non-invasive prenatal diagnosis of at-risk pregnancies.
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Introduction
Pre-eclampsia is one of the most common causes of pre-term birth and
fetal growth restriction, as well as being a major cause of maternal death
worldwide (Ghulmiyyah and Sibai, 2012). While the underlying causes
of pre-eclampsia are heterogeneous, there is generally a failure of
placental trophoblast cells to sufﬁciently invade and remodel maternal
arteries, which may be triggered by a failed immuno-response at the
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maternal-fetal interface (Redman and Sargent, 2010). This causes poor
perfusion leading to physiological and gene expression changes in re-
sponse to hypoxia and re-oxygenation stress (Tal, 2012). Early detection
and management is key to preventing maternal death and helping to
maintain the pregnancy, thus postponing premature birth.While a com-
bination of maternal serum markers (e.g. PAPP-A, Inhibin, ADAM12)
and Doppler ultrasound can be useful to identify women at risk for
pre-eclampsia in the ﬁrst trimester (Kuc et al., 2011), the high false
positive rate and lack of a consensus for preventative intervention of
pre-eclampsia makes the implementation of such screening impractical
at this point. Improvements in the early diagnosis of pre-eclampsia and
development of new therapies depend on a better understanding of
the underlying biology.
Clinically, pre-eclampsia is characterized by hypertension (.140/
90 mmHg) and proteinuria (.0.3 g/day). While the level of protein in
the urine is often used to identify cases of ‘severe’ pre-eclampsia (at
greatest risk of adverse outcomes), this measurement is not always reli-
able (Cote et al., 2008). Amore valuable subclassiﬁcation may be that of
early-onset pre-eclampsia (EOPET) (diagnosis prior to 34 weeks) and
late-onset pre-eclampsia (LOPET) (diagnosis after 34 weeks gestation)
(von Dadelszen et al., 2003). There is accumulating evidence that
these are distinct entities (Rolfo et al., 2010; Bahado-Singh et al., 2012;
Escudero et al., 2013) with placental pathology playing a greater role in
EOPET (Cross, 2003). Gene expression changes have also been used
to sub-classify pre-eclampsia into three major molecular proﬁles (Cox
et al., 2011) although their relationship to clinical classiﬁcations
(EOPET versus LOPET, severe versus not) was not provided. Pre-
eclampsia is a common cause of intrauterine growth restriction (IUGR)
and it has been suggested that normotensive IUGR (nIUGR) may be
associated with similar placental ﬁndings (Huppertz, 2011), but it is not
clear if there is truly a shared etiology or just overlapping features.
Asalteredgeneexpression isobserved inpre-eclampsia-associatedpla-
centas (Louwen et al., 2012), we expect alteredDNAmethylation to also
be prevalent, based on thewell-established link between gene expression
and DNA methylation. Studying DNA methylation changes in these pla-
centas provides a useful adjunct to characterize the pathological changes
and to identify clinical subgroups of patients with differing underlying eti-
ology. DNA methylation may also be useful in the development of new
early screening approaches to identify at-risk pregnancies (Yuen et al.,
2011). LackofDNAmethylationat genepromoters is generally associated
with the potential for gene transcription (Weber et al., 2007). However,
gene expression levels may be further modulated by DNA methylation
at upstream enhancer sites (Horiuchi et al., 2012), which can affect
the binding of transcription factors, and/or at the shores of cytosine-
guanine dinucleotide (CpG) islands (Irizarry et al., 2009). We and others
previously showed that EOPET-associated placentas exhibit hypomethy-
lation at a number of gene promoter regions compared with controls in
placenta (Yuen et al., 2010; Jia et al., 2012); Pre-eclamptic pregnancies
were also associated with hypomethylation in maternal blood vessels
(Mousa et al., 2012). However, our previous study was based on a small
number of placentas (n ¼ 4 EOPET placentas) and relatively small
number of CpG sites tested genome-wide (n ¼ 1506) (Yuen et al.,
2010). Another study also showed altered methylation in pre-eclampsia
placentas (n ¼ 9) using a genome-widemethylatedDNA immunoprecipi-
tation approach, but did not distinguish clinical subtypes of pre-eclampsia
(Jiaetal., 2012).Furthermore, these studiesdidnot compare theseﬁndings
to gene expression of the complete candidate gene set.
In the present study, we sought to follow-up our initial ﬁndings (Yuen
et al., 2010) with a larger set of EOPET and control placentas (n ¼ 20 in
each group) and use of a more comprehensive microarray interrogating
485 512 sites covering 99% of known genes. Importantly, this newer
array includes sites in enhancers and promoter ‘shore’ regions, which
were less prevalent in previous arrays andmaybepreferentially indicative
of changes in gene expression. We used these data to (i) evaluate the
ability of DNA methylation to distinguish clinical subgroups of pre-
eclampsia and (ii) characterize the underlying biological pathways
involved in these molecular changes and their potential relationship to
changes observed in association with hypoxia exposure.
Methods
Ethical approval
This studywas performedwith the ethics approval of theUniversity of British
Columbia/Children’s & Women’s Health Centre of British Columbia Re-
search Ethics Board.
Sample collection
Whole chorionic villi were sampled from placentas delivered at Women’s
Hospital in Vancouver, Canada. Clinical criteria for EOPET were deﬁned
using the Canadian guidelines (Magee et al., 2008). For DNA methylation
analysis, samples were further sub-classiﬁed by the presence/absence of
severe proteinuria (.3 g/day), coincident IUGR, gestational diabetes and
HELLP syndrome, deﬁned by hemolysis, elevated liver enzymes and low
platelet count. IUGRwasdeﬁned as (i) birthweight below the third percentile
for gender and gestational age using Canadian population parameters or (ii)
birthweight below the 10th percentilewith persistent uterine artery notching
at 22–25weeks, absent or reversed end diastolic velocity on umbilical artery
Doppler, or oligohydramnios. As gestational age is a large determinant of
DNA methylation in the placenta (Novakovic et al., 2011), it is critical that
placentas from pre-eclamptic pregnancies are compared with gestational
age-matched controls (Yuen et al., 2010).We therefore compared with pla-
centas obtained from chromosomally normal losses or births due to amix of
etiologies (premature rupture of membranes, loss of amniotic ﬂuid and cer-
vical incompetence) with no evidence of placental abnormality based on a
pathological exam (Table I; Supplementary data, Table SI). The use of such
pre-term samples is validated by our previous observation that the DNA
methylation proﬁles of these premature-controlsweremore similar to term-
controls than to the gestational age (GA) age-matched EOPET placentas
(Yuen et al., 2010). Chorionic villi from at least two sites (center and perim-
eter) on the fetal sideof theplacentawere sampled, rinsedofmaternal blood.
DNA was extracted from each and combined in equal quantities for better
........................................................................................
Table I Clinical information of samples used in Illumina
methylation array.
EOPET (n 5 20)
mean (range)
CONTROL
(n 5 20) mean
(range)
P-value
Gestational age
(weeks)
31.8 (24.9–37.3) 31.8 (25.0–37.3) 0.931
Maternal age
(years)
33.5 (19.7–42.9) 31.5 (22.2–38.7) 0.289
Birthweight (g) 1451 (440–3685) 1940 (758–3470) 0.052
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representation of placenta-wide changes. It should be noted that four of the
samples in this study have been previously assessed for methylation changes
(using less-comprehensive microarrays) (Yuen et al., 2009, 2010).
Illumina HumanMethylation450 BeadChip
Twenty EOPET samples and 20 controls in two batches (2 batches of 10
EOPET versus 10 controls) were used for the Illumina HumanMethylation450
BeadChip (Bibikova et al., 2011) (Illumina, Inc., SanDiego,CA,USA) (hereafter
referred to as the ‘450 K array’). Of note, 750 ng of DNA was bisulﬁte con-
verted using the EZ DNA Methylation Kit (Zymo Research, Irvine, CA,
USA). Hybridization of samples was performed following manufacturer’s
protocol. Chips were scanned by a HiScan 2000 or iScan (Illumina). Raw
and processed data have been deposited into the publically accessible
database, GEO (GSE44667; http://www.ncbi.nlm.nih.gov/geo/). Raw data
were read into GenomeStudio 2011 (Illumina) where background subtraction
and initial processing was performed. Probes targeting a CpGwith a documen-
ted single nucleotide polymorphism in the C or Gwere removed from analysis
(Price et al., 2013). Probes targeting the sex chromosomeswere also removed.
Any probe that had a missing b-value or .0.01 detection P-value (probes
whose signal intensity was lower than background levels) in one sample was
also removed from analysis (n¼ 25 804). This left 430 685 probes for analysis.
Signal intensities were read into R v2.14 (R Development Core Team, 2011)
using methylumi (Davis et al., 2011) to create M-values (log transformations
proportional to the level of methylation). Values from remaining probes
were color channel corrected (Du et al., 2010), separated into Types I and
II probes and normalized by subset-quantile within array normalization
(Maksimovic et al., 2012). M-values were transformed back to b-values
(a value between 0 and 1 representing the fraction of methylated DNA) for
genome-wide analysis. Finally, probes that map away from their intended
target were removed from the ﬁnal candidate dataset (Price et al., 2013).
Gene expression microarray
Gene expression data were obtained using a subset of EOPET samples and
controls (n¼ 8 each) that were also run on the 450 K array. RNA was
extracted from placental villi stored in RNAlater at 2808C using an RNeasy
kit (Qiagen, Heiden, Germany). RNAwas assessed for quality on a Bioanalyzer
2100 (Agilent, Santa Clara, CA, USA), reverse-transcribed to cDNA and
hybridized to HT-12v4 Expression BeadChip (Illumina) following the manufac-
turer’s protocol. This chip interrogates over 47 000 transcripts genome-wide.
Raw data were quantile normalized in GenomeStudio 2011. Probes with
bad detection P-values (.0.01) in all samples were removed from analysis
(n ¼ 13 125). Data points from valid probes with a bad detection P-value
were removed and replaced with a value of one to represent a lack of expres-
sion. Expression values from the gene expression microarray were log2-
transformed before statistical analysis. Raw and processed data have been
deposited into the publically accessible database, GEO (GSE44711).
Pyrosequencing
Asubset of siteswith highly signiﬁcant differences from the array and/or rele-
vance for prenatal screening or hypoxia was followed up by bisulﬁte pyrose-
quencing of EOPET samples (n ¼ 20), other disease states (LOPET (n ¼ 21)
and nIUGR (n ¼ 17)) and a larger set of controls covering a broad range of
gestational ages (n ¼ 93). Assays (Supplementary data, Table SII) were
designed using PSQ Assay design (Biotage, Upsalsa, Sweden) and run on a
Qiagen Pyromark Q96 MD (Qiagen).
Statistical analysis
All statistical analysis was performed using R v2.14 (R Development Core
Team, 2011). Statistically signiﬁcant probes from the 450 K array were deter-
mined using the false discovery rate (FDR), which is an approach that is used to
correct for multiple testing. For this, signiﬁcance analysis of microarrays (SAM)
wasperformedonM-values using the siggenes package (Schwender, 2011). To
enrich for biological relevance, highly signiﬁcant probes were determined by
Db (difference in DNA methylation between cases and controls) in conjunc-
tion with an FDR cutoff. Principal component analysis (PCA) from the methy-
lumi package (Davis et al., 2011)was usedon subsets of the 450 K array data to
determine stratiﬁcation of the samples using several different parameters.
Signiﬁcant probes from the gene expression array were identiﬁed by SAM
using an FDRcutoff of 0.05 combinedwith a fold change of≥1.2.Correlation
of gene expression to DNA methylation was determined using Pearson’s
correlation on the subset of samples used in both arrays.
DNAmethylation detected by pyrosequencing was conﬁrmed as concord-
ant to that of the 450 K array using Pearson’s correlation (average r ¼ 0.80).
Pearson’s correlation was then used on the pyrosequencing data to assess if
DNA methylation was affected by gestational age. If so, statistical signiﬁcance
was assessed by analysis of covariance (ANCOVA) with gestational age as
thecovariate.Bonferroni correctedpair-wisepost hocanalysisdeterminedstat-
istical signiﬁcance in DNA methylation between individual sample groups.
A x2 test was used to determine whether probes in speciﬁc genomic ele-
mentswereoverrepresented inourdatasetwhencomparedwith the arrayas
a whole.
Bioinformatics
The database for annotation, visualization and integrated discoverywas used
to conduct geneontology analysis (Huang da et al., 2009). Signiﬁcant biologic-
al processes were elucidated by over-representation of genes in gene ontol-
ogy categories. Next, genomic sequences spanning 50 bp up- and
downstream of signiﬁcant CpG sites were extracted using Galaxy (https://
main.g2.bx.psu.edu). These sequences were submitted for recurrent motif
discovery using multiple em for motif elicitation (MEME) suite (Bailey et al.,
2009). Recurrent motifs were then queried for known transcription factor
binding motifs using the TOMTOM tool in MEME suite.
Results
ExtensiveDNAmethylationproﬁle changes in
early-onset pre-eclampsia
Principle component analysis was performed using all 430 685 probes
(Supplementary data, Fig. S1) to determine the differences in the
overall DNA methylation proﬁle between cases and controls. Samples
clustered roughly according to the presenceor absenceof pre-eclampsia
rather than by gestational age, surprisingly because gestational age has
been shown todrive dramatic differences inDNAmethylation (Novako-
vic et al., 2011).This implies thatDNAmethylation changes inEOPETare
very dramatic and widespread throughout the genome. However, it
should be noted that the majority (65%) of cases were within a narrow
GA range of 31–34 weeks.
Overall, an extremely large number of CpG sites (over 100 000)
showed statistically signiﬁcant differences between groups at an FDR
of ,0.05, suggesting dramatic epigenetic effects of EOPET on the pla-
centa. Most array studies use a combination of signiﬁcance (e.g. FDR
of ,0.01 or 0.05) in combination with a cutoff for mean difference
(Db) to detect the most biologically meaningful changes. As there is no
standard set of criteria, we considered various combinations of Db
values and FDRs to establish values that would allow us to focus on
the most signiﬁcant probes for the follow-up (Table II). Changing the re-
quirement forDb has a dramatic effect on the number of signiﬁcant can-
didates,with1312candidatesusingDbof0.1 andonly 87candidateswith
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Db of 0.15. Based on this analysis we opted to focus our analysis using a
relatively stringent cutoff of 12.5%Db and 1% FDR, providing a list of 286
CpGs that were differentially methylated in placental samples between
EOPET and controls. After elimination of four probes that map to mul-
tiple locations in the genome, 282 candidate CpGs located in or near
248 genes remained.
Of the candidateCpGs, 74.5%were hypomethylated and 25.5%were
hypermethylated in EOPET as compared with controls (Supplementary
data, Table SIII). Among the genes associated with hypomethylated
CpGswere several coding for proteins suggested to beuseful inmaternal
serum screening for pre-eclampsia including INHBA (2 CpGs), ADAM12,
PAPPA2 (3 CpGs) and FLT1, as well as several genes we previously
reported as exhibiting hypomethylation in pre-eclampsia (e.g. TIMP3,
MEST, CXCL9) (Yuen et al., 2010). However, many of the altered
CpGs were associated with genes of unknown placental function.
EOPET, but not associated clinical features,
presents a distinct DNAmethylation proﬁle
To assess the discriminatory power of the identiﬁed EOPET-associated
DNAmethylation changes, PCAwas repeated on all samples using only
the 282 candidate CpGs (Fig. 1). This revealed a distinct clustering of
EOPET samples separate from controls along principal component 1
(40% of the variance). However, there was more variability among the
EOPET samples than the controls. In order to determine if some of
this variability was due to clinical variation in samples, we further
coded samples by the presence or absence of IUGR, severe proteinuria,
diabetes or HELLP syndrome. However, there were no distinct clusters
of these clinical subtypes or sex using this set of probes (Fig. 1).
We also comparedDNAmethylation proﬁles between EOPET placen-
tas with (n¼ 12) and without (n ¼ 8) concurrent IUGR. No sites were
found to be signiﬁcant using modest criteria of an FDR ≤0.05 and
Db ≥ 5%, in contrast to the large number of sites signiﬁcant using such
criteria when comparing EOPET versus controls. Separately comparing
each subset of EOPET samples depending on the presence/absence of
IUGR, against corresponding gestational age-matched controls produced
similar sets of signiﬁcant probes as the EOPET group as a whole (analysis
not shown). Hence, we ﬁnd no evidence for a major methylation differ-
ence between EOPET with and without associated IUGR.
Differentially methylated loci showed
negative correlation with gene expression
A subset of placental samples run on the DNA methylation array (eight
EOPET versus eight controls) was deemed of sufﬁcient quality to be run
on an Illumina HT-12v4 Expression BeadChip array. There were 195
Figure1 Principle component analysis based upon values of the 282 signiﬁcant differentiallymethylatedprobes in this study. EOPETand control samples
form distinct clusters (circled), with no additional clustering based on the presence of IUGR, severe proteinuria, hemolysis, elevated liver enzymes and low
platelet count (HELLP) or gestational diabetes. Sex of sample is indicated by m or f.
..................................................................
........................................................................................
Table II Number of candidate sites, without removing
cross-mapping probes, obtained using different cutoff
parameters for Db and FDR.
FDR Db cutoff
Cutoff 0% 10% 12.5% 15%
1 – 1333 313 88
0.1 154 604 1328 312 87
0.05 102 343 1312 311 87
0.01 38 840 1175 286 82
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probes representing 182 genes that were signiﬁcantly changed using a
cutoff of ≤0.05 FDR and ≥1.2–fold change (Supplementary data,
Table SIV). Similarly, 17.4% of 282 candidate CpGs from the 450 K
methylation array (87.9% of which were represented on the expression
array) were associated with signiﬁcantly altered gene expression using a
nominal P-value of 0.05 (Supplementary data, Table SIII). There were
multiple genes signiﬁcantly over-expressed in this study that have been
shown as over-expressed in other pre-eclampsia genome-wide expres-
sion studies despite differing sample criteria andmethods (Louwen et al.,
2012). These common genes include: INHA, LEP, PAPPA2, CGB, CRH,
HTRA4, TREM1, CXCR6, EBI3, BTNL9, ULBP1, SIGLEC6 and QPCT.
In addition, 23of the282candidateCpGsshowednegativecorrelation
between DNA methylation and gene expression (P, 0.05) (Supple-
mentary data, Table SIII), although some of the associated genes did
not reach genome-wide statistical signiﬁcance for differential expression
between cases and controls. These signiﬁcant genes included EPAS1,
FLT1 and FLNB, which are known to be important for angiogenesis.
This further supports the involvement of DNA methylation in the regu-
lation of a substantial number of genes that are associated with pre-
eclampsia development. Small sample size likely caused an underestima-
tion of altered methylation sites associated with altered expression.
Changes in gene expression can also be regulated by other factors (e.g.
availability of transcription factors) in addition to DNA methylation,
and can change at term in response to labor and delivery, confounding
these comparisons.
Differences in DNAmethylation are regional
and different in related disorders
The ability to determine molecular differences speciﬁc to disease type is
important for establishing accurate prediction methods and targeted
treatment. Thus, bisulﬁte pyrosequencing of four altered CpG sites
was performed on placentas from EOPET, LOPET, nIUGR and controls
(Fig. 2). These four siteswerechosen for further investigationdue to their
large Db and previous evidence that their expression can be affected by
hypoxia (BHLHE40 (Chakrabarti et al., 2004) and SLC2A1 (Baumann
et al., 2007)) or is relevant to prenatal screening (INHBA and ADAM12)
(Kuc et al., 2011). While in some of these genes only one of the asso-
ciated CpGs fulﬁlled the criteria of FDR , 0.01 and ≥12.5%Db, exam-
ining all array targets in these genes also showed DNA methylation
differences between EOPET placentas and controls in nearby targets
(Fig. 3). Comparing the DNA methylation at the signiﬁcant CpG sites
to expression in each gene revealed statistically signiﬁcant negative cor-
relation in BHLHE40, and trends in SLC2A1 and ADAM12 (Fig. 4). The
increased expression reﬂects the expected association of decreased
methylation near the promoter region of these genes.
DNA methylation for all four genes showed a small but signiﬁcant
negative correlation with increasing gestational age; therefore, all statis-
tical tests were performed using gestational age as a co-variate. It should
be noted that EOPET showeddecreasedDNAmethylation at these loci,
theopposite directionof that expected if gestational age inﬂuenced these
changes. Each gene showeda statistically signiﬁcant difference (P, 0.05)
Figure 2 Boxplots from pyrosequencing follow-up of candidate CpGs associated with four genes. (A) INHBA (cg11079619); (B) BHLHE40
(cg20971407); (C) SLC2A1 (cg01924561) and (D) ADAM12 (cg02494582). Percent methylation is indicated on the Y-axis. Analysis of covariance
(ANCOVA) adjusting for gestational age followedbyBonferroni corrected pair-wise post hoc analysiswasused to determine signiﬁcancebetween individual
groups *P, 0.05, **P, 0.01 and ***P, 0.001.
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between groups, with EOPET being signiﬁcantly different from the con-
trols for all genes, conﬁrming the array ﬁndings. LOPET showed signiﬁ-
cant alterations compared with controls for INHBA, BHLHE40 and
SLC2A1, while only BHLHE40 showed a statistical difference between
nIUGR and controls.
EOPETshowshypomethylationat loci thatare
hypermethylated with hypoxia exposure
EOPET is associated with initial placental hypoxia followed by
re-oxygenation stress (Hung et al., 2002); thus, we wanted to assess
whether sites altered by hypoxia exposure in culture would also be
altered in pre-eclampsia. We recently used the 450 K array to assess
DNA methylation changes in cultured trophoblast cells exposed to
three oxygen levels (Yuen et al., 2013). Of the strictly deﬁned subset
of 282 altered CpGs associated with EOPET, only ﬁve overlapped with
those identiﬁed as signiﬁcant changes upon exposure of cells to
hypoxia. However, 78.3% of probes identiﬁed as signiﬁcant in the
hypoxia study are considered signiﬁcantly different between EOPET
and control samples when using a less strict t-test P-value cutoff of
0.05. However, these CpGs all demonstrated increased DNAmethyla-
tion upon exposure to hypoxia in cytotrophoblast, whereas these same
loci showed decreased DNA methylation in pre-eclampsia. As many of
these same loci are hypermethylated in syncytiotrophoblast as com-
pared with cytotrophoblast (Yuen et al., 2013), these results could
also reﬂect an alteration in trophoblast cell populations in EOPETplacen-
tas (i.e. reduced cytotrophoblast:syncytiotrophoblast ratio).
We further performed PCAusing just the 147 hypoxia-associated loci
to determine if EOPETand control placentaswould cluster into separate
groups using this subset of loci. A separation of EOPET and control pla-
centaswas achievedwith fewoutliers (Fig. 5).Again, therewasno further
separation of cases based on clinical subclassiﬁcation of EOPET.
Genomic regional and functional enrichments
of differentially methylated CpG sites
Investigatingwhether signiﬁcantCpGsare located in certain genomicele-
ments such as CpG islands or enhancers can help elucidate the nature of
Figure 3 DNAmethylation levels for cases and controls according to genomic location. Genomic order of CpGs is given on the X-axis. CpG islands are
assigned according toUCSCGenomeBrowser delineations. Each plot represents one candidate gene: INHBA (A), BHLHE40 (B), SLC2A1 (C) and ADAM12
(D). Asterisk indicates candidate CpG site. Candidate CpGs fell into a variety of genomic regions relative to the gene structure.
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the biological processes that are disrupted in EOPET (Fig. 6). Signiﬁcantly
more probes fell into enhancer regions from among our candidate sites
than expected at random from the array. There are also proportionally
fewerprobes falling intohigh-densityCpG islands, typically unmethylated
and associated with gene promoters, than non-CpG islands. Enhancers
are often located outside of CpG islands, explaining the enrichment of
signiﬁcant probes in lowCpG density areas. There is no signiﬁcant differ-
ence fromtheexpected ratios inprobesthat fall into intermediatedensity
CpG islands or CpG island shores.
Of signiﬁcant CpG sites, 29.8% are located in ‘intergenic regions’,
which are deﬁned using the Illumina annotation as being further than
2 kb from the transcription start or end site of a gene; however upstream
enhancers could be located in such intergenic regions (Sanyal et al.,
2012). As it is unclear without functional studies on placental tissue
whether an upstream enhancer has an effect on expression or not, we
associated all unannotated signiﬁcantCpGswith theclosest transcription
start site to a RefSeq gene (Price et al., 2013) to expose potential tran-
scriptionally important regions for future studies.
Gene ontology analysis for DNA methylation returned a list of
enriched biological processes (Table III, Supplementary data, Table
SV). The top signiﬁcant gene ontology clusters were involved in
regulation of gene transcription, implying an overall disregulation of tran-
scription factors affecting gene expression in EOPET placentas. Consist-
ent with this, invocation of the hypoxia response pathway targets many
transcription factors (Schodel et al., 2011). Many of the genes associated
with these gene ontology terms are affected by oxygen levels or directly
involved in the hypoxia response pathway (e.g. EPAS1). Differentiation
and morphogensis were also signiﬁcant ontology terms, consistent
with the observed altered development of trophoblast in pre-eclampsia
(Gauster et al., 2009). Gene ontology analysis for gene expression
returned only one hit of P, 0.01: ‘female pregnancy’ (GO:0007565).
Consistent with this, many of the genes in this category have been
shown to be over-expressed in pre-eclampsia as detectable in maternal
serum (e.g. PAPPA) (Kuc et al., 2011).
MEME identiﬁed two recurrent motifs in proximity to the signiﬁcant
CpGs. These twomotifs each occurred in 28 of 282 sites. To determine
if they were associated with a transcription factor binding site, the
sequences were submitted to TOMTOM, where the transcription
factordatabases JASPARanduniprobewere searched for corresponding
deﬁned motifs. There were no signiﬁcant occurrences of speciﬁc tran-
scription factor motifs, consistent with there being a wide range of tran-
scription factors that may be affected by the pre-eclamptic state.
Figure 4 Methylation at candidate sites is compared with gene expression. Results for four genes are given: INHBA (A), BHLHE40 (B), SLC2A1 (C) and
ADAM12 (D). The expected negative correlation in methylation and gene expression exists for BHLHE40, with similar trends in SLC2A1 and ADAM12.
DNA hypomethylation in early-onset pre-eclampsia 703
Discussion
In this study, we demonstrate widespread alterations in DNA methyla-
tion in placentas from pregnancies complicated by EOPET. This
expands upon and conﬁrms our previous report of altered methylation
in EOPET (Yuen et al., 2010) with much larger sample size and
numberof analyzed loci. EOPETcases canbedistinguished fromcontrols
based on thismethylation proﬁle, regardless of the presence/absence of
additional features (e.g. IUGR, severe proteinuria and HELLP). These
ﬁndings support the concept of EOPET being a distinct clinical entity
that includes various presentations including HELLP syndrome.
Clinical criteria for the deﬁnition of ‘severe’ pre-eclampsia vary
(Steegers et al., 2010) with some based on a gestational age cutoff
(i.e. EOPET), and others based on levels of proteinuria (e.g. .2 g/day)
(Nishizawa et al., 2011). In our study, some cases classiﬁed as EOPET
Figure 5 Principle component analysis using CpG sites that are signiﬁcantly altered in cultured cytotrophoblast exposed to hypoxic conditions for 24 h
(Yuen et al., 2013). Control and pre-eclampsia samples had a tendency to cluster apart from each other. Sex of sample is indicated by m or f.
........................................................................................
Table III Gene Ontology top 10 hits for genes with
altered DNAmethylation.
GONumber Term Count P-value
GO:0006355a regulation of transcription,
DNA-dependent
43 4.35E-05
GO:0051252a regulation of RNA metabolic
process
43 7.32E-05
GO:0030182b neuron differentiation 16 5.05E-04
GO:0010628a positive regulation of gene
expression
18 1.26E-03
GO:0045941a positive regulation of
transcription
17 2.39E-03
GO:0010604a positive regulation of
macromolecule metabolic
process
22 3.09E-03
GO:0006928b cell motion 15 3.16E-03
GO:0045449a regulation of transcription 49 3.93E-03
GO:0000904b cell morphogenesis involved in
differentiation
10 4.13E-03
GO:0010557a positive regulation of
macromolecule biosynthetic
process
18 4.30E-03
aTerms that are related to gene transcription.
bTerms that are involved in cell differentiation.
Figure 6 Comparison of proportions of signiﬁcant (candidate) CpGs
relative to the array as a whole that fall into different genomic elements.
The elements compared include high CpG density islands (HC), inter-
mediate CpG density islands (IC), intermediate density CpG islands
that are on the shore of an HC (ICshore), low CpG density regions
(LC) and annotated genomic enhancers. **P, 0.01 and ***P, 0.001.
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did not have documented proteinuria (i.e. diagnosis was based on the
presence of hypertension in combination with other ﬁndings such as
fetal IUGR as per Canadian guidelines (Magee et al., 2008)) while
others had heavy proteinuria (.3 g/day); however, no relationship
between proteinuria level and methylation proﬁle was identiﬁed.
Other conditions concurrentwith EOPET in this study (IUGR, gestation-
al diabetes and HELLP syndrome) did not cluster separately from other
EOPET samples. Consistent with this observation, HELLP syndrome
has been shown to have a similar transcription proﬁle as pre-eclampsia
(Varkonyi et al., 2011). Thus, theremay be consistentmolecular features
of EOPET placentas despite variability in clinical symptoms; this vari-
ability may be reﬂective of other factors such as maternal health.
When comparing LOPET and nIUGR for a subset of loci, EOPET
showed the largest differences from controls, but LOPET and nIUGR
trended towards EOPET for these genes. In a separate study using
these samples, but focusing on stress and other hormonal pathway
genes, LOPET samples similarly tended to exhibit levels of methylation
overlapping EOPET and control values, suggesting this may be a hetero-
geneous group with a subset of cases possibly ﬁtting an ‘EOPET-like’
pattern and the remainder not (Hogg et al., 2013a, b). Furthermore, pre-
vious studies have shown that genes associated with altered DNA
methylation or expression in EOPET show fewer and smaller changes
in LOPET and/or nIUGR (Nishizawa et al., 2007; Yuen et al., 2010;
Hogg et al., 2013a, b). It has been suggested that LOPET and EOPET
have distinct etiologies (von Dadelszen et al., 2003; Rolfo et al., 2010),
with EOPET having greater placental dysfunction (Chen et al., 2012).
The present data support the concept of greater placental dysregulation
in EOPET, though this needs to be followed up in amore comprehensive
manner.
Detecting the future onset of pre-eclampsia early in pregnancy could
lead to improved management and help mitigate the effects of the dis-
order. Ideally, the detection methodwould be non-invasive, likely inves-
tigating components of a ﬁrst trimester maternal serum sample. Altered
maternal serum concentrations of a number of proteins have been
reported (PAPP-A, ADAM12, hCG, Inhibin, PP13, sFLT1, Endoglin,
PGF, Leptin (Kuc et al., 2011; Kleinrouweler et al., 2012; Masoura
et al., 2012; Hogg et al., 2013a, b)) prior to the onset of pre-eclampsia,
with the placenta being the likely source of many of these. Expression
of several genes coding for up-regulated proteins is increased in pre-
eclampsia placentas from the 3rd trimester (ADAM12, LEP, CGB,
PAPPA, INHA) as indicated in this and other studies (Louwen et al.,
2012). Altered DNA methylation in many of the genes coding for
these proteins was observed in the present study including ADAM12,
CGA, FLT1, INHBA and, using a lower Db cutoff of 8%, PAPPA and LEP.
We also found a correlation of DNA methylation and gene expression
for most of these genes in this study. Hence, other genes we identiﬁed
as showing altered DNA methylation, could perhaps offer candidates
to investigate as potential biomarkers in maternal serum for the
enhanced prediction of pre-eclampsia.
Furthermore, methylation differences could be utilized for early
screening using an approach based on circulating cell-free fetal DNA
(cffDNA), which is increased in mothers predisposed to pre-eclampsia
(Zeybek et al., 2012). We previously suggested that methylation of
TIMP3 was a candidate for DNA methylation-based diagnosis based
upon the differential DNAmethylation patterns between blood and pla-
centa, with more extreme values in EOPET-associated placentas (Yuen
et al., 2010); a ﬁnding conﬁrmedbyothers (Xiang et al., 2012). Some sites
showing similar properties to those in the present study include
BHLHE40 and INHBA. Further evaluation of such sites for their ability
to enhance the early detection of EOPET over simply quantifying the
cffDNA fraction (Yuen et al., 2011) would be of interest.
There are several potential drivers for the altered DNA methylation
observed in this study. One key driver is oxygen tension
(hypoxia/re-oxygenation), an etiological factor in the development of
pre-eclampsia (Hung et al., 2002). The hypoxia response pathway
involves the expression of many genes, including the hypoxia-inducible
factors (HIFs), transcription factors designed to activate geneswhose ex-
pression can help reestablish viable oxygen levels.EPAS1, which encodes
for HIF2a, is an early factor in the hypoxia response pathway and has
been shown to be active in pre-clampsia placentas (Rajakumar et al.,
2001). CpGs in the shore of the promoter CpG Island of this gene
were signiﬁcantly hypomethylated in pre-clampsia placentas in this
study, indicating that there is increased binding of transcription factors
such as RNA polymerase (Ogoshi et al., 2011). Supporting this, EPAS1
was over-expressed in this and a previous study (Jarvenpaa et al.,
2007). Frequent targets of HIF2a are BHLHE40 and INHBA (Schodel
et al., 2011), both of which code for proteins that can prevent tropho-
blast differentiation (Meinhardt et al., 2005; Ezashi et al., 2012).
BHLHE40 was shown to have signiﬁcantly decreased DNA methylation
in the shoreof theCpG islandpromoter and increased expression in pre-
clampsia placentas, while INHBA showed decreased DNA methylation
directly in the promoter region and has demonstrated increased expres-
sion in several studies (Enquobahrie et al., 2008; Sitras et al., 2009;Hoegh
et al., 2010; Nishizawa et al., 2011; Tsai et al., 2011).
Wepreviously demonstrated that a subset of genes underwent hyper-
methylation upon exposure of cytotrophoblast cells to 24 h of ,1%
oxygen (Yuen et al., 2013). Many of these same genes became hypo-
methylated upon differentiation of cytotrophoblast to syncytiotropho-
blast, consistent with the observation that hypoxia can block the
differentiation of cytotrophoblast cells into syncytiotrophoblast (Alsat
et al., 1996). In the present study, we found that these hypoxia/differen-
tiation sites tended to be hypomethylated in EOPET,which is the oppos-
ite of what would be expected due to hypoxic exposure. It may be that
re-oxygenation stress, also proposed to occur in the development of
pre-eclampsia, may result in hypomethylation of these same loci. It has
been hypothesized that this sudden change in physiological state later
in pregnancy can induce a stress response in the trophoblast (Hung
et al., 2002), potentially changing the DNAmethylation of the chorionic
villi. It is also possible that the short-term effects of reduced oxygen level
in culture do not accurately reﬂect the long-term effects in vivo. Reduced
DNAmethylation is in fact observedwith long-termhypoxic exposure in
some cancer tissues (Shahrzad et al., 2007).
Hypomethylation of these hypoxia-associated loci could be evidence
of altered cell composition as many of these CpG sites were signiﬁcantly
hypomethylated in syncytiotrophoblast comparedwith cytotrophoblast;
however, an excess of cytotrophoblast is generally observed (Redline
and Patterson, 1995) in pre-eclampsia, making this explanation less
likely. Other potential drivers of altered DNA methylation changes
include effects of common treatments given to these women such as
the prescription of anti-hypertensivemedication or corticosteriod treat-
ments, the latter given for fetal lung maturation before delivery. The
effects of anti-hypertensive medicine on DNA methylation in the pla-
centa are unstudied; however there are clear disruptions in the cortico-
steroid pathways in these samples (Hogg et al., 2013a, b), perhaps from
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the use of antenatal corticosteriods. As these are not individual events,
but logically succeed one another, a mix of these factors driving the
DNA methylation differences is plausible.
There are limitations to this study.Toavoidconfoundingby gestational
age—associated methylation changes (Novakovic et al., 2011), control
placentas were also obtained from premature births. DNAmethylation
changes could theoretically be associated with pre-term labor or
pre-term rupture of membranes, whichwere some causes of premature
births in these controls. Furthermore, pre-eclampsia might have devel-
oped in some of these pregnancies had they continued further to
term. Nonetheless, the tight clustering of control placentas relative to
the EOPET ones, suggests they are a relatively homogenous group.
Another limitation comes from the difﬁculty in obtaining high-quality
RNA from placentas. We were only able to obtain quality RNA from 8
of the 20 EOPET samples, each matched to a control, resulting in
reduced power when studying expression versus DNA methylation in
this sample set.
By investigating theDNAmethylation proﬁle of pre-eclampsia placen-
tas, this studyhas laid the groundwork for future studies. Asmanyaltered
CpG sites located in upstream enhancer sites were identiﬁed, functional
studies investigating DNA methylation-dependent regulation at these
sites would help determine the biological signiﬁcance of these ﬁndings.
Furthermore, candidate genes could be investigated for altered expres-
sion in maternal blood or for properties appropriate for development of
DNAmethylation-basednon-invasiveprenatal screeningmethods.Add-
itionally, a more thorough genome-wide investigation of DNAmethyla-
tion differences in LOPET and nIUGR samples would help elucidate the
natureof anypotential alterations in placentalmethylation proﬁle and the
nature of the overlap with EOPET.
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